An observational study in Inflammatory Bowel Disease, Crohn's Disease and Ulcerative Colitis, sponsored by Merck Sharp & Dohme LLC. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Observational
This study is being done to assess the clinical course and treatment options for Crohn's Disease (CD) and ulcerative colitis (UC) in the populations of Eastern Europe, Middle East, and North Africa.
1,073 studies on the registry are indexed under Colitis; 131 are open to participants now.
Browse Colitis studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,114 studies on the registry; 132 are open to participants now.
Of its 489 completed or terminated interventional studies of FDA-regulated products, 362 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
All patients with CD or UC who visit the study sites in Eastern Europe, Middle East, and North Africa during the study period will be asked to participate.
Inclusion Criteria:
All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
Other: No intervention.
There is no study intervention. Participants will be treated locally per site standards.
The number of participants with Crohn's Disease (CD) or ulcerative colitis (UC) who visit the participating sites.
Time frame: 1 Year
The number of participants with different degrees of CD and UC severity.
Time frame: 1 Year
Use rates of classes of drug therapy.
Time frame: 1 Year
Number and types of surgical interventions.
Time frame: 1 Year
Outcomes of surgical intervention.
Time frame: 1 Year
No study locations are listed for this record.
This study is withdrawn, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.